These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 10126586)

  • 1. Pharmacoeconomic series: Part 3. Applying pharmacoeconomic and quality-of-life measures to the formulary management process.
    Skaer TL
    Hosp Formul; 1993 Jun; 28(6):577-84. PubMed ID: 10126586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic analysis in formulary decisions: an international perspective.
    Johnson JA; Bootman JL
    Am J Hosp Pharm; 1994 Oct; 51(20):2593-8. PubMed ID: 7847423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
    Bukstein DA
    Am J Manag Care; 1997 Nov; 3(11):1701-6. PubMed ID: 10178468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to use structured decision making in developing therapeutic, cost-effective formulary systems.
    Crane VS
    Hosp Formul; 1993 Oct; 28(10):859-62, 865-7. PubMed ID: 10129135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulary decision making: identifying factors that influence P&T committee drug evaluations.
    Segal R; Pathak DS
    Hosp Formul; 1988 Feb; 23(2):174-8. PubMed ID: 10286022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formularies: the role of pharmacy-and-therapeutics (P&T) committees.
    Summers KH; Szeinbach SL
    Clin Ther; 1993; 15(2):433-41; discussion 432. PubMed ID: 8519049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to develop critical paths and prepare for other formulary management changes.
    McCaffrey S; Nightingale CH
    Hosp Formul; 1994 Sep; 29(9):628-32, 635. PubMed ID: 10137059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P & T Committee interview: strategies to ensure an effective formulary system.
    Riff L; Hutchinson R
    Hosp Formul; 1988 Nov; 23(11):901-4, 907-8. PubMed ID: 10290754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to develop a proactive formulary system.
    Crane VS; Gonzalez ER; Hull BL
    Hosp Formul; 1994 Oct; 29(10):700-2, 704-8, 710. PubMed ID: 10137847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survey of selective administration procedures in formulary maintenance.
    Quigley MA; Brown WM
    Hosp Pharm; 1981 Jul; 15(7):371-4, 378-80. PubMed ID: 10252001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of pharmacoeconomics to formulary decision making in managed care organizations.
    Suh DC; Okpara IR; Agnese WB; Toscani M
    Am J Manag Care; 2002 Feb; 8(2):161-9. PubMed ID: 11858228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The military health services system model for pharmacoeconomic decision making.
    Ries AJ; Potyk RP; Brier KL; Miller MR; Tornow JJ; Weber MP; Finder SF; Reeves CS
    Med Interface; 1995 May; 8(5):132-7. PubMed ID: 10142786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P & T Committee formulary requests: criteria for admission.
    Weintraub M; Guttmacher L
    Hosp Formul; 1984 Oct; 19(10):975-7, 980. PubMed ID: 10268315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost and quality considerations in antibiotic formulary management.
    Ritchie DF
    Pharm Pract Manag Q; 1996 Jul; 16(2):4-8. PubMed ID: 10161610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining the formulary status of quinolone antibiotics: one institution's approach.
    Nightingale CH; Lubowski T; On A; Quintiliani R
    Hosp Formul; 1992 May; 27(5):509-10, 513-4, 516. PubMed ID: 10128710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing an effective P & T Committee, Part 2.
    Abramowitz PW; Godwin HN; Latiolais CJ; McDougal TR; Miller WA; Ravin RL
    Hosp Formul; 1985 Oct; 20(10):1071-2, 1078-81, 1086 passim. PubMed ID: 10273830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Issues in formulary management: therapeutic interchange. The value, cost, and quality of therapeutic interchange.
    Mahoney CD
    Hosp Formul; 1992 Oct; 27 Suppl 2():2-3. PubMed ID: 10122035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomics and the formulary decision-making process.
    Bakst A
    Hosp Formul; 1995 Jan; 30(1):42-50. PubMed ID: 10172201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulary management at a tertiary-care facility: P&T committee interview.
    Lucas RV; Abramowitz PW
    Hosp Formul; 1988 Feb; 23(2):162-8, 172-3. PubMed ID: 10286021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.